Azenta, Inc. (AZTA)

Azenta, Inc. (AZTA) Healthcare & Pipeline Overview

Azenta, Inc. delivers sample exploration and management solutions for the life sciences industry, offering both products and services. With a global presence and a focus on cold chain solutions and sample-based laboratory services, Azenta supports pharmaceutical, biotechnology, and research clients in optimizing their research and development workflows.

What Is the Investment Thesis for AZTA?

Azenta, Inc. presents a compelling, albeit high-risk, investment case within the life sciences sector. The company's dual approach, offering both products and services for sample management, positions it to capitalize on the growing demand for efficient research and development workflows. While Azenta's gross margin of 44.6% indicates a solid foundation, the negative profit margin of -29.9% raises concerns about profitability and operational efficiency. Key growth catalysts include expanding its service offerings and penetrating further into the Asia Pacific market. However, investors should closely monitor the company's ability to improve its bottom line and manage its relatively high beta of 1.47, reflecting higher volatility compared to the market. The company's transformation from Brooks Automation to Azenta signals a strategic shift towards life sciences, but its success depends on effectively executing this transition and achieving sustainable profitability.

Based on FMP financials and quantitative analysis

AZTA Key Highlights

• Market capitalization of $1.19B, reflecting its current valuation in the life sciences market.
• Gross margin of 44.6%, indicating a solid foundation in its product and service offerings.
• Negative profit margin of -29.9%, signaling challenges in achieving profitability.
• Beta of 1.47, suggesting higher volatility compared to the broader market.
• Operates in two segments: Life Sciences Products and Life Sciences Services, providing a diversified revenue stream.

Who Are AZTA's Competitors?

AZTA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AZTA's Key Strengths?

• Comprehensive service offerings covering both products and services.
• Strong presence in key geographic markets, including North America, Europe, and Asia Pacific.
• Established relationships with major pharmaceutical and biotechnology companies.
• Expertise in cold chain logistics and sample management.

What Are AZTA's Weaknesses?

• Negative profit margin indicating challenges in achieving profitability.
• High beta suggesting higher volatility compared to the market.
• Dependence on the life sciences industry, making it vulnerable to industry downturns.
• Potential for increased competition in the sample management market.

What Could Drive AZTA Stock Higher?

• Expansion of genomic sequencing services to meet growing demand.
• Penetration of the Asia Pacific market through strategic partnerships.
• Development of integrated cold chain solutions to enhance sample integrity.
• Enhancement of informatics capabilities to provide advanced data analytics.
• Expansion into new therapeutic areas, such as cell and gene therapy by Q4 2026.

What Are the Key Risks for AZTA?

• Negative return on equity (-10.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Economic downturns affecting research and development spending in the life sciences industry.
• Increased competition from other sample management providers.
• Regulatory changes impacting the storage and handling of biological samples.
• Technological advancements rendering existing solutions obsolete.
• Negative profit margin indicating challenges in achieving profitability.

What Are the Growth Opportunities for AZTA?

• Expanding Genomic Sequencing Services: Azenta can capitalize on the growing demand for genomic sequencing by expanding its service offerings. The global genomic sequencing market is projected to reach $25.5 billion by 2028, growing at a CAGR of 12.7% from 2021. By investing in advanced sequencing technologies and bioinformatics capabilities, Azenta can attract more pharmaceutical and biotechnology clients seeking comprehensive genomic data analysis for drug discovery and personalized medicine. This expansion can be realized within the next 2-3 years.
• Penetrating the Asia Pacific Market: The Asia Pacific region represents a significant growth opportunity for Azenta. The increasing investments in healthcare and research infrastructure in countries like China and India are driving demand for sample management solutions. By establishing strategic partnerships and expanding its sales and marketing presence in the region, Azenta can tap into this rapidly growing market. This expansion could contribute significantly to revenue growth over the next 3-5 years.
• Developing Integrated Cold Chain Solutions: As the demand for temperature-sensitive biological samples increases, Azenta can focus on developing integrated cold chain solutions that ensure the integrity of samples throughout the entire supply chain. The global cold chain logistics market is expected to reach $447.5 billion by 2025. By offering comprehensive cold chain management services, including temperature monitoring, storage, and transportation, Azenta can differentiate itself from competitors and capture a larger share of the market. This initiative can be implemented within the next 1-2 years.
• Enhancing Informatics Capabilities: Azenta can enhance its informatics capabilities to provide customers with advanced data analytics and insights. The increasing volume of data generated in life sciences research requires sophisticated tools for data management and analysis. By developing user-friendly software platforms and offering customized data analytics services, Azenta can help its clients extract valuable insights from their samples and accelerate their research. This enhancement can be rolled out progressively over the next 2-4 years.
• Expanding into New Therapeutic Areas: Azenta can diversify its customer base by expanding its services into new therapeutic areas, such as cell and gene therapy. The cell and gene therapy market is experiencing rapid growth, driven by the development of innovative treatments for various diseases. By offering specialized sample management solutions tailored to the unique needs of cell and gene therapy companies, Azenta can tap into this high-growth market segment. This expansion can be strategically pursued over the next 3-5 years.

What Opportunities Does AZTA Have?

• Expanding into new therapeutic areas, such as cell and gene therapy.
• Penetrating further into the Asia Pacific market.
• Developing integrated cold chain solutions for temperature-sensitive samples.
• Enhancing informatics capabilities to provide advanced data analytics.

What Threats Does AZTA Face?

• Economic downturns affecting research and development spending in the life sciences industry.
• Increased competition from other sample management providers.
• Regulatory changes impacting the storage and handling of biological samples.
• Technological advancements rendering existing solutions obsolete.

What Are AZTA's Competitive Advantages?

• Specialized Expertise: Deep understanding of sample management and cold chain logistics in life sciences.
• Comprehensive Solutions: Offers both products and services, providing a one-stop solution for customers.
• Established Customer Base: Long-standing relationships with major pharmaceutical and biotechnology companies.
• Technological Innovation: Continuous investment in advanced technologies for sample management and analysis.

What Does AZTA Do?

Azenta, Inc., established in 1978 and formerly known as Brooks Automation, Inc., rebranded in December 2021 to emphasize its focus on life sciences. Headquartered in Burlington, Massachusetts, Azenta operates globally, providing critical solutions in North America, Europe, China, and the Asia Pacific. The company is structured into two primary segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems crucial for storing compounds and biological samples. Additionally, this segment provides equipment for sample preparation and handling, alongside consumables and instruments designed to aid customers in managing samples throughout their research, discovery, and development processes. The Life Sciences Services segment delivers comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services. These services are designed to advance scientific research and support drug development, including sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, and biospecimen procurement. Azenta serves a diverse clientele, including pharmaceutical companies, biotechnology firms, biorepositories, and research institutes, positioning itself as a key enabler in the life sciences sector.

What Products and Services Does AZTA Offer?

• Provides automated cold sample management systems for storing biological samples.
• Offers equipment for sample preparation and handling.
• Supplies consumables and instruments for managing samples.
• Delivers comprehensive sample management programs.
• Provides integrated cold chain solutions to maintain sample integrity.
• Offers genomic sequencing and gene synthesis services.
• Provides laboratory processing and analysis services.
• Offers biospecimen procurement services.

How Does AZTA Make Money?

• Sells automated cold sample management systems and related equipment.
• Provides sample management services, including storage, sequencing, and analysis.
• Generates revenue through contracts with pharmaceutical, biotechnology, and research institutions.
• Offers customized solutions tailored to specific customer needs.

What Industry Does AZTA Operate In?

Azenta, Inc. operates within the medical instruments and supplies industry, a segment experiencing steady growth driven by advancements in biotechnology and pharmaceutical research. The market is characterized by intense competition and continuous innovation. Companies like SYRE: Spyre Therapeutics, Inc. are also active in the broader life sciences space, focusing on therapeutic development. Azenta differentiates itself by providing comprehensive sample management solutions, catering to the increasing need for efficient and reliable sample handling in drug discovery and development. The industry is further influenced by regulatory requirements and the growing demand for personalized medicine, creating both opportunities and challenges for Azenta.

Who Are AZTA's Key Customers?

• Pharmaceutical companies involved in drug discovery and development.
• Biotechnology companies focused on research and development.
• Biorepositories storing biological samples for research purposes.
• Research institutes conducting scientific research.

Net buyingInsider Activity

Over the past six months, Azenta, Inc. insiders filed 11 SEC Form 4 transactions — 1 sales and 10 purchases. On net that is roughly 71K shares acquired (about $1.2M) — insiders putting money in tends to read as conviction.

FY2026 estForward Outlook

Wall Street analysts project Azenta, Inc. revenue of about $600.5M for fiscal 2026, with EPS near $0.45. The estimate reflects 4 contributing analysts.

F-Score 3/9Financial Health

Azenta, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.31 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE -11%Key Financial Metrics

Return on equity for Azenta, Inc. stands at -10.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -9.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 2.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.83 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.3%, the inverse of the P/E and a quick read on earnings relative to price.

Azenta, Inc. (AZTA) Valuation Context

Valued at $1.19B, AZTA is classified as a small-cap stock. Relative to its peer group, AZTA's quantitative score of 59/100 is roughly in line with the peer average of 65/100.

AZTA Revenue & Earnings Trend

In Q1 2026, AZTA generated $144.8M in top-line revenue, marking a sequential decrease of 2.6%. The company recorded a net loss of $160.8M, with diluted EPS of $-3.49. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, AZTA averaged $-0.99 in diluted EPS.

Company Profile

Azenta, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Burlington, US. The company is led by CEO John Marotta. AZTA has traded publicly since 1995.

AZTA Financials

AZTA Latest News

AZTA Analyst Consensus

AZTA MoonshotScore

Common Questions About AZTA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources